Daewoong pharmaceutical Co.,Ltd

KSE 069620.KS

Daewoong pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2023: USD 102.46 M

Daewoong pharmaceutical Co.,Ltd Operating Income is USD 102.46 M for the year ending December 31, 2023, a 127.13% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Daewoong pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2022 was USD 45.11 M, a 95.22% change year over year.
Daewoong pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2021 was USD 23.11 M, a 48.24% change year over year.
Daewoong pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2020 was USD 15.59 M, a -59.53% change year over year.
Daewoong pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2019 was USD 38.52 M, a 75.39% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

KSE: 069620.KS

Daewoong pharmaceutical Co.,Ltd

CEO	Mr. Chang-Jae Lee
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	12, Bongeunsa-ro 114-gil
Employees	1,710
Sector	Health Care
Industries Pharmaceuticals

Description

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years